CytoDyn, Inc. is pushing to develop the CCR5 antagonist leronlimab for a wide range of indications, including HIV, cancer and COVID-19, but the effort has hit a roadblock at the US Food and Drug Administration. The company announced on 13 July that it has received a refusal to file letter from the FDA for its first biologics license application for leronlimab for highly treatment experienced HIV patients.
The update casts more doubts on CytoDyn's development plan for leronlimab, which has already faced some stumbling blocks. The company...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?